Erin Mulvihill
E-Card
Erin Mulvihill
Associate Professor
BSc, Microbiology and Immunology, University of Western Ontario
PhD, Biochemistry, University of Western Ontario
Postdoctoral Fellowship, Mount Sinai Hospital, Lunenfeld Tanenbaum Research Institute
Room: University of Ottawa Heart Institute, 40 Ruskin Street, Room H3228, Ottawa, ON K1Y 4W7
Office: 613-696-7221
Work E-mail: emulvihi@uottawa.ca
Work E-mail: emulvihill@ottawaheart.ca
Biography
Research Interests
Over 25% of Canadians live with pre-T2DM or T2DM (> 11 million patients) and this expanding population is at ever greater risk for heart disease causing a significant strain on health care resources (costs >16 billion/year in Ontario alone). With her expertise in lipids and lipoproteins, models of diabetes and cardiovascular disease, intestinal biology and mouse genetics, Dr. Mulvihill’s laboratory aspires to contribute improve our understanding of the molecular events which contribute to metabolic and cardiovascular disease.
Select Publications
- Cellular Sites and Mechanisms Linking Reduction of Dipeptidyl Peptidase-4 Activity to Control of Incretin Hormone Action and Glucose Homeostasis. Mulvihill EE, Varin EM, Gladanac B, Campbell JE, Ussher JR, Baggio LL, Yusta B, Ayala J, Burmeister MA, Matthews D, Bang KW, Ayala JE, Drucker DJ. Cell Metab. 2017;10;25(1):152-165.
- Inhibition of Dipeptidyl Peptidase-4 Impairs Ventricular Function and Promotes Cardiac Fibrosis in High Fat-Fed Diabetic Mice. Mulvihill EE, Varin EM, Ussher JR, Campbell JE, Bang KW, Abdullah T, Baggio LL, Drucker DJ. Diabetes. 2016;65(3):742-54.
- TCF1 links GIPR signaling to the control of beta cell function and survival. Campbell JE, Ussher JR, Mulvihill EE, Kolic J, Baggio LL, Cao X, Liu Y, Lamont BJ, Morii T, Streutker CJ, Tamarina N, Philipson LH, Wrana JL, MacDonald PE, Drucker DJ. Nat Med. 2016;22(1):84-90.
- Naringenin prevents obesity, hepatic steatosis, and glucose intolerance in male mice independent of fibroblast growth factor 21.Assini JM, Mulvihill EE, Burke AC, Sutherland BG, Telford DE, Chhoker SS, Sawyez CG, Drangova M, Adams AC, Kharitonenkov A, Pin CL, Huff MW. Endocrinology. 2015;156(6):2087-102.
- Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection. Ussher JR, Baggio LL, Campbell JE, Mulvihill EE, Kim M, Kabir MG, Cao X, Baranek BM, Stoffers DA, Seeley RJ, Drucker DJ. Mol Metab. 2014;9;3(5):507-17.
- Naringenin prevents cholesterol-induced systemic inflammation, metabolic dysregulation, and atherosclerosis in Ldlr⁻/⁻ mice. Assini JM, Mulvihill EE, Sutherland BG, Telford DE, Sawyez CG, Felder SL, Chhoker S, Edwards JY, Gros R, Huff MW. J Lipid Res. 2013;54(3):711-24.
- GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. Panjwani N, Mulvihill EE, Longuet C, Yusta B, Campbell JE, Brown TJ, Streutker C, Holland D, Cao X, Baggio LL, Drucker DJ. Endocrinology. 2013;154(1):127-39.
- Nobiletin attenuates VLDL overproduction, dyslipidemia, and atherosclerosis in mice with diet-induced insulin resistance. Mulvihill EE, Assini JM, Lee JK, Allister EM, Sutherland BG, Koppes JB, Sawyez CG, Edwards JY, Telford DE, Charbonneau A, St-Pierre P, Marette A, Huff MW. Diabetes. 2011;60(5):1446-57.
- Naringenin decreases progression of atherosclerosis by improving dyslipidemia in high-fat-fed low-density lipoprotein receptor-null mice. Mulvihill EE, Assini JM, Sutherland BG, DiMattia AS, Khami M, Koppes JB, Sawyez CG, Whitman SC, Huff MW. Arterioscler Thromb Vasc Biol. 2010;30(4):742-8.
- Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor-null mice with diet-induced insulin resistance. Mulvihill EE, Allister EM, Sutherland BG, Telford DE, Sawyez CG, Edwards JY, Markle JM, Hegele RA, Huff MW. Diabetes. 2009;58(10):2198-210.
